

Performance Report

Genesis Oncology Trust
For the year ended 30 June 2017

Prepared by C & A Accounting Services Limited

Contents

| | |
|----|------------------------------------|
| 3 | Compilation Report |
| 4 | Entity Information |
| 6 | Approval of Financial Report |
| 7 | Statement of Service Performance |
| 8 | Statement of Financial Performance |
| 9 | Statement of Financial Position |
| 10 | Statement of Cash Flows |
| 11 | Statement of Accounting Policies |
| 13 | Notes to the Performance Report |
| 15 | Independent Audit Report |

Compilation Report

Genesis Oncology Trust For the year ended 30 June 2017

Compilation Report to the Board of Trustees of Genesis Oncology Trust.

Scope

On the basis of information provided and in accordance with Service Engagement Standard 2 Compilation of Financial Information, we have compiled the financial statements of Genesis Oncology Trust for the year ended 30 June 2017.

These statements have been prepared in accordance with the accounting policies described in the Notes to these financial statements.

Responsibilities

The Trustees are solely responsible for the information contained in this financial report and have determined that the accounting policies used are appropriate to meet your needs and for the purpose that the financial statements were prepared.

The financial statements were prepared exclusively for your benefit. We do not accept responsibility to any other person for the contents of the financial statements.

Independence

We have no involvement with Genesis Oncology Trust other than for the preparation of financial statements and management reports and offering advice based on the financial information provided.

Disclaimer

We have compiled these financial statements based on information provided. Accordingly, we do not accept any responsibility for the reliability, accuracy or completeness of the compiled financial information contained in the financial statements. Nor do we accept any liability of any kind whatsoever, including liability by reason of negligence, to any person for losses incurred as a result of placing reliance on this financial report.

C&A Accounting Services Ltd

C & A Accounting Services Limited

12a Jack Conway Avenue

Manukau

Auckland 2104

Entity Information

Genesis Oncology Trust For the year ended 30 June 2017

Charitable Purpose and Scope of Genesis Oncology Trust

Genesis Oncology Trust is a registered charity whose purpose is to provide grants to the cancer control community. The purpose of the grants is to support New Zealand-based initiatives that will lead to improvements in the prevention, detection, diagnosis or treatment of cancer, or improvements in palliative care for people who suffer from cancer.

Legal Name of Entity

Genesis Oncology Trust

Entity Type and Legal Basis

Charity

Registration Number

CC23672

Entity's Purpose or Mission

The Genesis Oncology Trust invites applications for grants to support New Zealand-based initiatives that will lead to improvements in the prevention, detection, diagnosis or treatment of cancer, or improvements in palliative care and for professional education.

The Trust provides grants to doctors and scientists conducting cancer research, and to medical and scientific cancer-control personnel for their professional development and education.

Entity Structure

The Trust comprises six (five since February 2017) trustees representing the medical, strategic and business aspects of Oncology who meet during the year. The Trustees are responsible for the financial and legal management of the trust and the approval of all grants.

Applications for funding are received and processed by the Trust's Executive Director. Applications are assessed for their scientific and educational merit by a ten-person Assessment Committee comprising clinical and radiation oncologists, biomedical researchers, a psychologist and a senior palliative care nursing specialist. The Executive Director manages and co-ordinates this committee, but does not vote.

At the end of each Assessment Committee meeting a list of applications ranked from highest to lowest is produced and this is presented to the Genesis Oncology Trust Board. A cut off for funding is suggested by the Assessment Committee, but the final decision is made by the Board.

Main Sources of Entity's Cash and Resources

The Trust has two sources of income, public donations and investment income. All money received via public donations is distributed in the form of grants. When required additional funds from investments are used to meet the Board approved budget for cancer control research and professional development.

Main Methods Used by Entity to Raise Funds

Prior to February 2016 there was direct communications with Genesis Energy customers - when they signed up as Genesis Energy Customers and through regular customer communications they were asked if they would like to contribute to the Trust via their monthly energy bill. Now that this income stream has been discontinued donors can donate by credit card via the Genesis Oncology Trust web site or by direct debit.

Entity's Reliance on Volunteers and Donated Goods or Services

All of the Trust's Board members are volunteers. The Trust Administrator, Christine Cleator is also a volunteer. Her primary roll is authorizing of the monthly accounts via internet banking.

Trustees during the 2016 - 2017 Financial year:

- Mr Albert Brantley (resigned January 2017)
- Dr Michael Jamieson
- Mr Robert Jay
- Ms Betsy Marshall
- Dr Ann Richardson
- Ms Maureen Shaddick

Physical Address

56 Whitehaven Road, Glendowie, Auckland, New Zealand, 1071

Postal Address

56 Whitehaven Road, Glendowie, Auckland, New Zealand, 1071

Approval of Financial Report

Genesis Oncology Trust For the year ended 30 June 2017

The Board of Trustees are pleased to present the approved financial report including the historical financial statements of Genesis Oncology Trust for the year ended 30 June 2017.

APPROVED



Maureen Shaddick

Trustee

Date 12 February 2018



Robert Jay

Trustee

Date 12 February 2018

Statement of Service Performance

Genesis Oncology Trust

For the year ended 30 June 2017

What did we do?, When did we do it?

The Trust provides grants to the cancer control community to support New Zealand-based initiatives that will lead to improvements in the prevention, detection, diagnosis or treatment of cancer, or improvements in palliative care. This is achieved through twice yearly peer-reviewed grant rounds. These take place in March/April and August through December each year.

Description of Outcomes

In the 2016/17 financial year the Trust received 76 applications totaling approximately \$3.3 million for funding to support cancer control research and professional development. After a rigorous and transparent peer-review process twenty five grants totaling \$944,998 were approved.

| | 2017 | 2016 |
|---|---------|---------|
| Description and Quantification of the Entity's Outputs | | |
| Grants Approved | 944,998 | 981,220 |

Description and Quantification of the Entity's Outputs

Twenty five grants totaling \$944,998 were approved in the 2016/2017 financial year. All grants approved are listed on the Trust's web site with short descriptions of the purpose of the grant. <https://www.genesisoncology.org.nz/funded-projects>

On the completion of research projects or professional education endeavour all grant recipients are required to provide a report. Where appropriate these are turned into PR material for posting on the Trust's web site.

Additional Output Measures

The first end point of biomedical and clinical research is publication of the results in peer reviewed medical and scientific journals and these publications are regularly forwarded to the Trust. The desirable end point is of course improvements in the prevention of, and reductions in mortality from, cancer. This is difficult to quantify in the short term, but the rate of new cancer diagnosis in New Zealand are decreasing and cancer survival rates are increasing, and the Trust believe the Trust has made a contribution to this improving situation.

Statement of Financial Performance

Genesis Oncology Trust

For the year ended 30 June 2017

| | NOTES | 2017 | 2016 |
|--|-------|------------------|------------------|
| Revenue | | | |
| Donations | 1 | 14,124 | 478,247 |
| Interest received | 1 | 514 | 1,677 |
| Other revenue | 1 | 1,159,486 | 780,402 |
| Total Revenue | | 1,174,124 | 1,260,326 |
| Expenses | | | |
| Costs related to providing donations | 2 | 272,756 | 196,174 |
| Grants and donations made | | | |
| Grants Approved | | 944,998 | 981,220 |
| Adjustments to Grants Approved | | (228,185) | (47,690) |
| Total Grants and donations made | | 716,813 | 933,530 |
| Total Expenses | | 989,568 | 1,129,704 |
| Surplus/(Deficit) for the Year | | 184,555 | 130,622 |

Statement of Financial Position

Genesis Oncology Trust As at 30 June 2017

'What the entity owns?' and 'What the entity owes?'

| | 30 JUN 2017 | 30 JUN 2016 |
|---|-------------------|-------------------|
| Assets | | |
| Current Assets | | |
| Bank accounts and cash | 30,808 | 47,674 |
| GST Receivable | 29,763 | 38,342 |
| Investments current | 169,199 | 134,688 |
| Total Current Assets | 229,769 | 220,705 |
| Non-Current Assets | | |
| Investments | 17,167,356 | 17,214,488 |
| Total Non-Current Assets | 17,167,356 | 17,214,488 |
| Total Assets | 17,397,125 | 17,435,193 |
| Liabilities | | |
| Current Liabilities | | |
| Creditors and accrued expenses | | |
| Trade and other payables | 7,736 | 195,337 |
| Grants with Conditions | 997,233 | 991,859 |
| Total Creditors and accrued expenses | 1,004,969 | 1,187,196 |
| Total Current Liabilities | 1,004,969 | 1,187,196 |
| Non-Current Liabilities | | |
| Other non-current liabilities | 355,122 | 395,517 |
| Total Non-Current Liabilities | 355,122 | 395,517 |
| Total Liabilities | 1,360,090 | 1,582,713 |
| Total Assets less Total Liabilities (Net Assets) | 16,037,035 | 15,852,480 |
| Accumulated Funds | | |
| Accumulated surpluses or (deficits) | 16,037,035 | 15,852,480 |
| Total Accumulated Funds | 16,037,035 | 15,852,480 |

Statement of Cash Flows

Genesis Oncology Trust For the year ended 30 June 2017

How the entity has received and used cash

Donations and investment income was used to fund research and professional development grants in the field of cancer control in New Zealand.

| Account | 2017 | 2016 |
|---|-----------------|------------------|
| Cash Flows from Operating Activities | | |
| Receipts from Donations | 14,124 | 555,442 |
| Receipts from Interest | 514 | 1,677 |
| Cash receipts from other operating activities | 1,159,486 | 780,402 |
| Goods & Services Tax | 8,579 | 16,479 |
| Payments to suppliers and employees | (460,356) | (8,537) |
| Cash flows from other operating activities | (751,834) | (1,167,645) |
| Total Cash Flows from Operating Activities | (29,487) | 177,818 |
| Cash Flows from Investing and Financing Activities | | |
| Receipts from sale of investments | 1,545,118 | 1,096,780 |
| Payments to purchase investments | (1,497,986) | (2,010,032) |
| Cash Flows from Other Investing and Financing Activities | (34,511) | 682,981 |
| Total Cash Flows from Investing and Financing Activities | 12,620 | (230,271) |
| Net Increase/ (Decrease) in Cash | (16,867) | (52,452) |
| Cash Balances | | |
| Cash and cash equivalents at beginning of period | 47,674 | 100,126 |
| Cash and cash equivalents at end of period | 30,808 | 47,674 |
| Net change in cash for period | (16,867) | (52,452) |

Statement of Accounting Policies

Genesis Oncology Trust For the year ended 30 June 2017

How did we do our accounting?

We use the accounting software "Xero". It is a cloud based accounting software system that integrates with our bank. It is an efficient and transparent method of processing both our day to day accounting needs and our annual financial reporting requirements.

Basis of Preparation

The entity has elected to apply PBE SFR-A (NFP) Public Benefit Entity Simple Format Reporting - Accrual (Not-For-Profit) on the basis that it does not have public accountability and has total annual expenses equal to or less than \$2,000,000. All transactions in the Performance Report are reported using the accrual basis of accounting. The Performance Report is prepared under the assumption that the entity will continue to operate in the foreseeable future.

Goods and Services Tax (GST)

The entity is registered for GST. All amounts are stated exclusive of goods and services tax (GST) except for accounts payable and accounts receivable which are stated inclusive of GST.

Income Tax

Genesis Oncology Trust is wholly exempt from New Zealand income tax having fully complied with all statutory conditions for these exemptions.

Bank Accounts and Cash

Bank accounts and cash in the Statement of Cash Flows comprise cash balances and bank balances (including short term deposits) with original maturities of 90 days or less.

Accounts Receivable

Accounts Receivable are stated at estimated realisable value. Amounts not considered recoverable are written off when identified as such.

Investments

The Trust's investment funds have been placed in Westpac's PremiumPlus Service Portfolio in the form of investment bonds and investment shares.

Investment bonds are recorded at cost and subsequently adjusted to fair value. Any premium or discount to maturity value is recognised as an interest expense/income over the remaining period to maturity.

Investment income is accounted for on an accrual basis.

Investment shares are initially recorded at cost and subsequently adjusted to fair value. Any fair value adjustments are treated as unrealised gains/losses in the statement of financial performance.

Distributions are recognised as they are received.

Donations Received

Donations are recognised on a cash receipts basis.

Grants & Distributions

Grants are included in the Statement of Financial Performance when approved by Trustees.

Foreign Currencies

Foreign currency transactions are recorded at the exchange rates in effect at the date of the transaction.

Financial Instruments

All financial instruments are recognised in the Statement of Financial Position. The Trust has not entered into any off-balance sheet instruments. The fair value of the financial instruments represents the carrying value of these items as recorded in the financial statements. The maximum exposure to credit risk is represented by the carrying value of each financial asset in the Statement of Financial Position.

Changes in Accounting Policies

There have been no changes in accounting policies. Policies have been applied on a consistent basis with those of the previous reporting period.

Notes to the Performance Report

Genesis Oncology Trust For the year ended 30 June 2017

| | 2017 | 2016 |
|---|------------------|----------------|
| 1. Analysis of Revenue | | |
| Revenue from providing donations | | |
| Donations Received | 14,124 | 478,247 |
| Total Revenue from providing donations | 14,124 | 478,247 |
| Interest, dividends and other investment revenue | | |
| Interest Received | 514 | 1,677 |
| Total Interest, dividends and other investment revenue | 514 | 1,677 |
| Other revenue | | |
| Portfolio Income | 1,159,486 | 780,402 |
| Total Other revenue | 1,159,486 | 780,402 |
| | 2017 | 2016 |

2. Analysis of Expenses

| | | |
|---|----------------|----------------|
| Costs related to providing donations | | |
| Accountancy Fees | 6,504 | 5,978 |
| Advertising | 78,495 | 1,950 |
| Audit Fee | 7,050 | 7,700 |
| Bank Charges | 1,043 | 303 |
| Computer Expenses | 40 | 2,419 |
| Computer Maintenance and Support | 1,121 | 22,837 |
| Conference Expenses | 3,141 | - |
| Consultants | 112,187 | 103,054 |
| Credit Card Charges | 252 | 320 |
| Freight & Courier | 112 | - |
| General Expenses | 330 | - |
| Home Office Costs | - | 238 |
| Investment Management Fees | 47,679 | 47,703 |
| Legal Expenses | 902 | - |
| Motor Vehicle Expenses | - | 563 |
| Office Expense | 85 | - |
| Postage | 148 | - |
| Telephone, Tolls & Internet | - | 40 |
| Travel Local | 6,466 | - |
| Web Payment Charges | 7,200 | 3,070 |
| Total Costs related to providing donations | 272,756 | 196,174 |

| | 2017 | 2016 |
|-------------------------------------|---------------|---------------|
| 3. Analysis of Assets | | |
| Bank accounts and cash | | |
| Bank Cheque Account | 30,671 | 44,541 |
| Bank Savings Account | 136 | 3,133 |
| Total Bank accounts and cash | 30,808 | 47,674 |

| | 2017 | 2016 |
|---|--------------|----------------|
| 4. Analysis of Liabilities | | |
| Creditors and accrued expenses | | |
| Accounts Payable (Xero) | 736 | 187,637 |
| Accounts Payable | 7,000 | 7,700 |
| Total Creditors and accrued expenses | 7,736 | 195,337 |

| | 2017 | 2016 |
|-------------------------------------|-------------------|-------------------|
| 5. Accumulated Funds | | |
| Accumulated Funds | | |
| Opening Balance | 15,852,480 | 15,721,858 |
| Accumulated surpluses or (deficits) | 184,555 | 130,622 |
| Total Accumulated Funds | 16,037,035 | 15,852,480 |
| Total Accumulated Funds | 16,037,035 | 15,852,480 |

6. Commitments

There are no commitments as at 30 June 2017 (Last year - nil).

7. Contingent Liabilities and Guarantees

There are no contingent liabilities or guarantees as at 30 June 2017 Last year - nil).

8. Related Parties

The trustees are not paid for their services to Genesis Oncology Trust. We estimate the value of their services for the year ended 30 June 2017 to be \$2000. (2016 \$2000)

9. Events After the Balance Date

There were no events that have occurred after the balance date that would have a material impact on the Performance Report (Last year - nil). Subsequent to year-end the Trustees have resolved to change the name of Genesis Oncology Trust to "Cancer Research Trust New Zealand".

10. Ability to Continue Operating

The entity will continue to operate for the foreseeable future.